CTOs on the Move

Covalon Technologies

www.covalon.com

 
Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon`s patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon`s technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.covalon.com
  • 1660 Tech Avenue Suite 5
    Mississauga, ON CAN L4W 5S7
  • Phone: 905.568.8400

Executives

Name Title Contact Details

Similar Companies

Nuo Therapeutics

Nuo Therapeutics, Inc. (formerly Cytomedix, Inc.) is a biomedical company that develops and commercializes individualized wound care therapies that harness a patient’s innate regenerative ability to stimulate wound healing. The Company’s flagship product, Aurix is a biodynamic hematogel derived from the patient’s own platelets and plasma, which is used at the point-of-care to jumpstart the natural healing process in a broad range of chronic wounds, including diabetic foot ulcers, venous leg ulcers and pressure ulcers (bedsores).

Baxter Sigma Spectrum Pumps

Baxter Sigma Spectrum Pumps is a Medina, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Halkey-Roberts Corporation

Halkey-Roberts Corporation is a Saint Petersburg, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Esprit Home Care

Esprit Home Care is a Leesburg, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

JenaValve

JenaValve Technology, Inc., based in Irvine, California and Munich, Germany develops, manufactures and markets transcatheter aortic valve implantation (TAVI) systems to treat patients suffering from aortic valve disease. The Company’s transapical TAVI system is CE marked and currently marketed in Europe and other markets worldwide and its new transfemoral TAVI system is currently undergoing clinical evaluation in Europe with a view toward achieving CE Mark in 2015. JenaValve is backed by world-class U.S., European and Asian investors, including Atlas Venture, Edmond de Rothschild Investment Partners, GIMV, NeoMed Management, Legend Capital, VI Partners, Sunstone Capital, Omega Funds, Biovest and Valiance Advisors.